Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test

Ted Driscoll

Congratulations to Natera—our portfolio company who is the leading innovator in prenatal genetic testing! Yesterday they announced a major deal with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostic information services company. Quest Diagnostics will offer physicians access to Panorama™, the new non-invasive prenatal test developed by Natera. (Read the Quest Press Release)

Panorama uses free-floating fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with . . .
→ Read full post: Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test

Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data

Ted Driscoll

February 20, 2013 source: the original post by Ed Silverman appeared in Pharmalot

As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But this poses challenges, of course, and Ted Driscoll, who heads the digital healthcare team at . . .
→ Read full post: Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data